The world leader in the field of biotechnology gets acquainted with the opinion of experts of the FSBI “NMIC Radiology” of the Ministry of Health of Russia

The delegation of the largest pharmaceutical company MSD (Merck Sharp & amp; Dohme, USA), headed by Senior Vice President of MSD, Director of the medical division of the company Dr. Elivar Barr, visited the Moscow Scientific Research Oncological Institute named after P.A.Herzen.
MSD is one of the leaders in the development and implementation of the latest drugs for medicine, including oncology. The visit of foreign pharmacists to the FSBI “NMIC of Radiology” of the Ministry of Health of the Russian Federation was not accidental – they were interested in the possibilities of the center for further cooperation in the field of clinical trials of new drugs, as well as the expert opinion of Russian colleagues on the use of Pembrolizumab (the newest drug in the treatment of melanoma and lung cancer) in various nosologies, which was undergoing clinical trials at the Herzen Institute.
Also during the meeting, the problems of vaccination prevention of tumor diseases, including those caused by the human papillomavirus, were discussed.
As Andrey Kaprin, Director General of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of the Russian Federation, noted at a meeting with foreign colleagues, the expansion of international cooperation, including the development of scientific and educational programs with MSD, will contribute to solving global problems in the fight against oncological diseases and developing ways to prevent them.

Press Service of the FSBI NMIC of Radiology of the Ministry of Health of Russia